ArticleCureus2026
Pembrolizumab-Associated Aortitis in a Patient With Triple-Negative Breast Cancer: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors have significantly improved outcomes across multiple malignancies; however, they can be associated with rare and potentially life-threatening immune-related adverse events. We report a case of a 47-year-old female with triple-negative breast cancer who developed acute epigastric and back pain with hemodynamic instability three days after receiving her fourth cycle of adjuvant pembrolizumab (last administered on July 14, 2025), leading to emergency department admission on July 17, 2025. Contrast-enhanced computed tomography revealed diffuse inflammatory thickening of the thoracic and abdominal aorta, consistent with aortitis, without aneurysm formation or stenosis. An extensive infectious and autoimmune workup was negative. Given the close temporal relationship with pembrolizumab exposure and exclusion of alternative etiologies, immune-mediated aortitis was suspected. High-dose intravenous corticosteroids followed by oral tapering led to rapid clinical improvement and normalization of inflammatory markers. Follow-up positron emission tomography-computed tomography demonstrated complete resolution of vascular inflammation, with no evidence of cancer recurrence. To our knowledge, this represents the first reported case of pembrolizumab-associated aortitis in a patient with triple-negative breast cancer, highlighting the importance of maintaining a high index of suspicion for immune-mediated vascular complications in patients receiving immune checkpoint inhibitors and underscoring the need for prompt diagnosis and treatment to prevent severe outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.